Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
20 hedge funds and large institutions have $1.73M invested in Kiromic BioPharma, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
55% less capital invested
Capital invested by funds: $3.82M → $1.73M (-$2.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55.3K |
| 2 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$49.4K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$39.5K |
| 4 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$21.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$17.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$511K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$71.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$32.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.9K |
KRBP Hedge Fund Activity: Q1 2022 in Review
20 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q1 2022, worth a combined $1.73M — down 55% from $3.82M a quarter earlier.
Fund positioning in KRBP was balanced in Q1 2022: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $55.3K. The largest seller was Sabby Management, cutting an estimated $511K.
- 20 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $1.73M of Kiromic BioPharma, Inc. Common Stock stock for Q1 2022, down 55% quarter-over-quarter.
- 2 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q1 2022 and 2 closed out, a net change of 0 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $55.3K added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q1 2022 was Sabby Management, an estimated $511K sold.
Based on aggregated 13F filings for Q1 2022.